|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
CUDC-101
Description of
CUDC-101: CUDC-101 is a multi-targeted, small-molecule
inhibitor of histone deacetylase (HDAC), epidermal growth factor
receptor tyrosine kinase (EGFR/ErbB1), and human epidermal growth factor
receptor 2 tyrosine kinase (HER2/neu or ErbB2) with potential
antineoplastic activity. HDAC/EGFR/HER2 inhibitor CUDC-101 inhibits the
activity of these three enzymes but the exact mechanism of action is
presently unknown. This agent may help overcome resistance to inhibition
of EGFR and Her2 through a simultaneous, synergistic inhibition of EGFR,
Her2, and HDAC. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus)
Current developer:
|
MedKoo Code#:
200841
|
|
Name:
CUDC-101
|
|
CAS#:
1012054-59-9
Synonym:
CUDC-101
IUPAC/Chemical name:
7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide
|
|
Chemical structure: |
Theoretical analysis
|
|
|
MedKoo Code#: 200841
Name: CUDC-101
CAS#: 1012054-59-9
Chemical Formula: C24H26N4O4
Exact Mass: 434.19541
Molecular Weight: 434.49
Elemental Analysis: C, 66.34; H, 6.03;
N, 12.89; O, 14.73
|
|
Availability and price:
CUDC-101
(99%) is in stock.
10 mg / $190.00
25 mg / $350.00
50 mg / $450.00
100 mg
/ $850.00
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
1. Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester,
Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng.
Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide
(CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for
the Treatment of Cancer. Journal of Medicinal Chemistry (2010), 53(5),
2000-2009. CODEN: JMCMAR ISSN:0022-2623. CAN 152:326271 AN 2010:170333
2. Morphy, Richard. Selectively Nonselective Kinase Inhibition: Striking
the Right Balance. Journal of Medicinal Chemistry (2010), 53(4),
1413-1437. CODEN: JMCMAR ISSN:0022-2623. CAN 152:183130 AN 2009:1315799
3. Cai, Xiong; Qian, Changgeng; Zhai, Haixiao; Bao, Rudi. Preparation of
4-phenylaminoquinazoline derivatives as epidermal growth factor receptor
tyrosine kinase (EGFR-TK) inhibitors containing a zinc binding moiety
and formulation containing them. U.S. Pat. Appl. Publ. (2009), 116 pp.
CODEN: USXXCO US 2009111772 A1 20090430 CAN 150:472748 AN 2009:524181
4. Cai, Xiong; Qian, Changgeng; Zhai, Haixiao. Preparation of tartaric
acid salts or complexes of quinazoline compounds containing a zinc
binding moiety as EGFR tyrosine kinase inhibitors. PCT Int. Appl.
(2009), 169pp. CODEN: PIXXD2 WO 2009035718 A1 20090319 CAN 150:352185 AN
2009:336937
5. Cai, Xiong; Qian, Changgeng; Gould, Stephen; Zhai, Haixiao.
Multi-functional small molecules as anti-proliferative agents and their
preparation. PCT Int. Appl. (2008), 494pp. CODEN: PIXXD2 WO 2008033747
A2 20080320 CAN 148:355828 AN 2008:353001
6. Qian, Changgeng; Cai, Xiong; Gould, Stephen; Zhai, Haixiao.
Preparation of quinazoline based EGFR inhibitors containing a zinc
binding moiety. PCT Int. Appl. (2008), 210 pp. CODEN: PIXXD2 WO
2008033749 A2 20080320 CAN 148:355813 AN 2008:351417
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
